Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 026: Nivolumab vs Chemotherapy in First-Line NSCLC
NCT02041533Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival in Participants With PD-L1 Expression >= 5% at 28 months. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02041533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041533.